Chugai Pharmaceutical Co (CHGCY) Fair Value & Analysis
Healthcare · US · Market cap $76.9B
Chugai Pharmaceutical Co
CHGCY · US
Fair value as of: Jul 15, 2026
From 26 valuation models · updated 10 days ago
Share price −4.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $19.71 – $33.48 · fair‑value band $10.66 – $22.33 · the $21.87 price screens above the $17.83 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Chugai Pharmaceutical Co (CHGCY) currently trades at $21.87, while our model-based Fair Value estimate is $17.83, implying the stock looks roughly 18.5% overvalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Chugai Pharmaceutical Co generated revenue of $1.3T at a net margin of 35.0%. Revenue grew 11.5% year over year. It earns a return on equity of 23.7%. The balance sheet holds a net cash position of $401B. Fundamentals as of Jul 15, 2026
Our scenario range runs from $10.66 (bear case) to $22.33 (bull case); at $21.87, the current price sits within that range. The share trades about 35% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -42% fair-value upside, at -18%, CHGCY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Chugai Pharmaceutical Co reported revenue of $1.3T in FY2025 versus $1,000B in FY2021, a compound +7.2%/yr. Reported net income was $455B in FY2025, compounding +10.7%/yr from FY2021.
Is CHGCY fairly valued? → Check now
Recent news
- Gero Reaches $34M in Equity Funding to Turn the Physics of Aging Into Medicines
- Immune Thrombocytopenia Market Forecast Signals Steady Growth During the Forecast Period (2026-2036) Backed by Pipeline Advancements | Delve
- Major Asian Stock Markets Fall Amid Renewed Middle East Tensions
- Sarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$77.92 | R$40.37 | -48% |
| Novartis AG NVSN | 2,601 MXN | 136.25 MXN | -95% |
| AstraZeneca PLC ZEG | €160.70 | €86.60 | -46% |
| Novo Nordisk A/S NOVOB | kr 326.90 | kr 409.46 | +25% |
| Amgen Inc AMGN34 | R$64.09 | R$51.29 | -20% |
| Gilead Sciences, Inc GILD | 2,263 MXN | 1,447 MXN | -36% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Chugai Pharmaceutical Co (CHGCY) undervalued?
What is the fair value of CHGCY?
What is the quality score of CHGCY?
What is the revenue of Chugai Pharmaceutical Co (CHGCY)?
What is the net profit margin of CHGCY?
Does Chugai Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Chugai Pharmaceutical Co analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.